세계의 난소암 진단 시장 규모 조사 및 예측: 진단 유형별, 암 유형별, 최종 용도별 및 지역별 분석(2023-2030년)

Global Ovarian Cancer Diagnostics Market is valued at approximately USD 1.53 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2023-2030. Ovarian cancer is a type of cancer that starts in the ovaries, which are the female organs responsible for producing eggs. This cancer is most commonly found in women aged 50 to 79 and is becoming more prevalent as the world's elderly population grows. Early detection and treatment are key in managing ovarian cancer, and initiatives by governments and organizations are driving market growth. However, a lack of skilled professionals hinder the market growth.

The increasing number of cases of ovarian cancer across the globe is driving the market. According to a report by the National Cancer Institute in the US, the rate of new cases of ovarian cancer is 10.3 per 100,000 women per year, with a death rate of 6.3 per 100,000 women per year. This shows how lethal this disease be. Governments and organizations are investing in research and development for ovarian cancer diagnosis and treatment which is boosting the market growth. such as the Ovarian Cancer Research Alliance (OCRA), a non-profit organization. Additionally, healthcare expenditure for cancer treatment is increasing, allowing patients to access advanced diagnostics and treatment for faster recovery. Market players are also launching innovative products, such as Inex Innovate's OvaCis Rapid test for ovarian cancer detection, which boosts the overall market growth. However, due to costlier cancer treatment it poses challenges to market growth. According to the report of the National Cancer Institute, in 2018, costs for cancer care were estimated at USD 201.19 billion, projected to increase to USD 208.9 billion in 2020 due to population growth and aging. This impact market growth until 2030.

The key regions considered for the Global Ovarian Cancer Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022. The region's growth can also be attributed to favorable government initiatives, increased healthcare expenditure, and the presence of key manufacturers. The American Cancer Society estimates that about 19,710 women in the US would be receiving a new diagnosis of ovarian cancer in 2023, with approximately 13,270 women dying from the disease. Ovarian cancer ranks fifth in cancer deaths among women, in U.S. Asia Pacific is expected to grow significantly over the forecast period, owing to factors such as overall economic development, improved healthcare infrastructure, increased disposable income, and greater consumer awareness.

Major market player included in this report are:

• Abcam plc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• AstraZeneca plc
• Siemens Healthcare GmbH
• Quest Diagnostics Incorporated.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Abbott. Laboratories Inc.

Recent Developments in the Market:

• In November 2022, Myriad Genetics Inc. announced, it had acquired Gateway Genomics, LLC to strengthen its portfolio of Women's Health products. This move aims to enhance their Women's Health products portfolio, providing personalized genetic tests that can be accessed during and after a woman's reproductive stage. With SneakPeek, Myriad can now offer genetic insights earlier in pregnancy, providing women with valuable data throughout their lifetime. The company's Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Scores for all ancestries are expected to increase revenue.
• In November 2022, Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay became the first IHC-based companion diagnostic to receive FDA approval. It can identify ovarian cancer patients eligible for ELAHERE, providing a new option for treatment.
• In November 2021, the USFDA approved an imaging drug called Cytalux (pafolcianine) that illuminates ovarian cancer tissue when exposed to fluorescent light, making it easier and more precise for surgeons to remove the cancer.

Global Ovarian Cancer Diagnostics Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Diagnosis Type, Cancer Type, End Use, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Diagnosis Type:

• Imaging
• Blood Test
• Biopsy
• Others

By Cancer Type:

• Epithelial Tumor
• Germ Cell Tumor
• Stromal Cell Tumor
• Others

By End Use:

• Hospital Laboratories
• Cancer Diagnostic Centers
• Research Institutes
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Ovarian Cancer Diagnostics Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Ovarian Cancer Diagnostics Market, by Diagnosis Type, 2020-2030 (USD Billion)
  • 1.2.3. Ovarian Cancer Diagnostics Market, by Cancer Type, 2020-2030 (USD Billion)
  • 1.2.4. Ovarian Cancer Diagnostics Market, by End Use, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Ovarian Cancer Diagnostics Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Ovarian Cancer Diagnostics Market Dynamics

• 3.1. Ovarian Cancer Diagnostics Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising prevalence of ovarian cancer
    • 3.1.1.2. Increasing emphasis on early diagnosis & treatment
    • 3.1.1.3. Increase in the number of initiatives by governments
  • 3.1.2. Market Challenges
    • 3.1.2.1. Lack of trained professionals
    • 3.1.2.2. High Cost of Diagnosis
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Increasing Healthcare Expenditure for Cancer Diagnosis and Treatment
    • 3.1.3.2. Innovative launches by the market players

Chapter 4. Global Ovarian Cancer Diagnostics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Ovarian Cancer Diagnostics Market, by Diagnosis Type

• 5.1. Market Snapshot
• 5.2. Global Ovarian Cancer Diagnostics Market by Diagnosis Type, Performance - Potential Analysis
• 5.3. Global Ovarian Cancer Diagnostics Market Estimates & Forecasts by Diagnosis Type 2020-2030 (USD Billion)
• 5.4. Ovarian Cancer Diagnostics Market, Sub Segment Analysis
  • 5.4.1. Imaging
  • 5.4.2. Blood Test
  • 5.4.3. Biopsy
  • 5.4.4. Others

Chapter 6. Global Ovarian Cancer Diagnostics Market, by Cancer Type

• 6.1. Market Snapshot
• 6.2. Global Ovarian Cancer Diagnostics Market by Cancer Type, Performance - Potential Analysis
• 6.3. Global Ovarian Cancer Diagnostics Market Estimates & Forecasts by Cancer Type 2020-2030 (USD Billion)
• 6.4. Ovarian Cancer Diagnostics Market, Sub Segment Analysis
  • 6.4.1. Epithelial Tumor
  • 6.4.2. Germ Cell Tumor
  • 6.4.3. Stromal Cell Tumor
  • 6.4.4. Others

Chapter 7. Global Ovarian Cancer Diagnostics Market, by End Use

• 7.1. Market Snapshot
• 7.2. Global Ovarian Cancer Diagnostics Market by End Use, Performance - Potential Analysis
• 7.3. Global Ovarian Cancer Diagnostics Market Estimates & Forecasts by End Use 2020-2030 (USD Billion)
• 7.4. Ovarian Cancer Diagnostics Market, Sub Segment Analysis
  • 7.4.1. Hospital Laboratories
  • 7.4.2. Cancer Diagnostic Centers
  • 7.4.3. Research Institutes
  • 7.4.4. Others

Chapter 8. Global Ovarian Cancer Diagnostics Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Ovarian Cancer Diagnostics Market, Regional Market Snapshot
• 8.4. North America Ovarian Cancer Diagnostics Market
  • 8.4.1. U.S. Ovarian Cancer Diagnostics Market
    • 8.4.1.1. Diagnosis Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Cancer Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. End Use breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Ovarian Cancer Diagnostics Market
• 8.5. Europe Ovarian Cancer Diagnostics Market Snapshot
  • 8.5.1. U.K. Ovarian Cancer Diagnostics Market
  • 8.5.2. Germany Ovarian Cancer Diagnostics Market
  • 8.5.3. France Ovarian Cancer Diagnostics Market
  • 8.5.4. Spain Ovarian Cancer Diagnostics Market
  • 8.5.5. Italy Ovarian Cancer Diagnostics Market
  • 8.5.6. Rest of Europe Ovarian Cancer Diagnostics Market
• 8.6. Asia-Pacific Ovarian Cancer Diagnostics Market Snapshot
  • 8.6.1. China Ovarian Cancer Diagnostics Market
  • 8.6.2. India Ovarian Cancer Diagnostics Market
  • 8.6.3. Japan Ovarian Cancer Diagnostics Market
  • 8.6.4. Australia Ovarian Cancer Diagnostics Market
  • 8.6.5. South Korea Ovarian Cancer Diagnostics Market
  • 8.6.6. Rest of Asia Pacific Ovarian Cancer Diagnostics Market
• 8.7. Latin America Ovarian Cancer Diagnostics Market Snapshot
  • 8.7.1. Brazil Ovarian Cancer Diagnostics Market
  • 8.7.2. Mexico Ovarian Cancer Diagnostics Market
• 8.8. Middle East & Africa Ovarian Cancer Diagnostics Market
  • 8.8.1. Saudi Arabia Ovarian Cancer Diagnostics Market
  • 8.8.2. South Africa Ovarian Cancer Diagnostics Market
  • 8.8.3. Rest of Middle East & Africa Ovarian Cancer Diagnostics Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Abcam plc.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. F. Hoffmann-La Roche Ltd.
  • 9.3.3. GlaxoSmithKline plc
  • 9.3.4. Johnson & Johnson Services, Inc.
  • 9.3.5. AstraZeneca plc
  • 9.3.6. Siemens Healthcare GmbH
  • 9.3.7. Quest Diagnostics Incorporated.
  • 9.3.8. Thermo Fisher Scientific Inc.
  • 9.3.9. Bio-Rad Laboratories Inc.
  • 9.3.10. Abbott. Laboratories Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption